Alopecia areata universalis showing excellent response to combination treatment modalities
DOI:
https://doi.org/10.66344/jpad.v32i2.1897Abstract
Alopecia areata (AA) is a non-scarring alopecia with mainly an autoimmune etiopathogenesis. The most severe AA variant is alopecia areata universalis (AAU), characterized by a total loss of scalp and body hair. AAU poses a significant psychosocial impact and may require combination therapy to provide satisfying results. A 15-year-old male presented with total loss of scalp and body hair in the last three years. Physical examination showed total alopecia with no terminal hairs nor scarring. Dermoscopic examination exhibited black dots, yellow dots, and empty follicles. The patient’s laboratory examination also indicated reactive anti-CMV IgG, anti-toxoplasma IgG, and anti-rubella IgG. The patient was then given combination treatment consisting of pulse-dose oral antivirus, inosine pranobex, topical corticosteroid and minoxidil, intralesional steroid injection, and light-emitting diode (LED) therapy. A course of 8-month-therapy showed significant improvement marked by hair regrowth. Diagnosis of AAU was established clinically, with viral infection thought to be one of the main triggering factors. The use of combination therapy was considered safe and effective for AAU patients, although the treatment might be continued long term. AAU is a disease that significantly impacts a patient’s quality of life. Its management requires comprehensive treatment and may need a combination of several treatment modalities.
References
1. Sterkens A, Lambert J, Bervoets A. Alopecia areata: A review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21:215-30.
2. Seetharam KA. Alopecia areata: An update. Indian J Dermatol Venereol Leprol. 2013;79:563-75.
3. Vafaie J, Weinberg JM, Smith B, et al. Alopecia in association with sexually transmitted disease: A review. Cutis. 2005;76:361-6.
4. Vano-Galvan S, Fernandez-Crehuet P, Grimalt R, et al. Alopecia areata totalis and universalis: A multicenter review of 132 patients in Spain. J Eur Acad Dermatol Venereol. 2017;31:550-6.
5. Kassira S, Korta DZ, Chapman LW, et al. Review of treatment for alopecia totalis and alopecia universalis. Int J Dermatol. 2017;56:801-10.
6. Legiawati L, Anissa L. Relapse in alopecia totalis after successful treatment with intralesional corticosteroid and oral immunomodulator. J Skin Stem Cell. 2020;7(1):e104841.
7. Pratt CH, King LE, Jr., Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.
8. Barton VR, Toussi A, Awasthi S, et al. Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2022;86(6):1318-34.
9. Sorbellini E, Rucco M, Rinaldi F. Photodynamic and photobiological effects of light-emitting diode (LED) therapy in dermatological disease: An update. Lasers Med Sci. 2018;33:1431-9.
10. Avci P, Gupta GK, Clark J, et al. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46:144-51.
11. Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: An autoimmune disease of multiple players. Immunotargets Ther. 2021;10:299-312.
12. Lai VWY, Chen G, Gin D, et al. Systemic treatments for alopecia areata: A systematic review. Australas J Dermatol. 2019;60:e1-e13.
13. Rajalakshmi R, Kumari R, Thappa DM. Acyclovir versus valacyclovir. Indian J Dermatol Venereol Leprol. 2010;76:439-44.
14. Lusiana, Legiawati L, Siphra V, Gaol EL, Surachmiati L, Sitohang IBS. Outcomes of oral immunotherapy for the treatment of alopecia areata totalis: A case report. In: Yunir E, editor. Medical case reports. New York: Nova Science Publishers; 2020.p.253-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Danny Surya, Lili Legiawati, Noer Kamila, Lis Surachmiati Suseno, Irma Bernadette Simbolon Sitohang
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
